METTL1 gene dosage and catalytic activity define a targetable vulnerability in pediatric cancers
METTL1 is responsible for catalyzing N7-methylguanosine (m7G) methylation of tRNAs. METTL1-dependent oncogenic mechanisms include both its methyltransferase catalytic activity and, in specific instances, non-catalytic interactions that maintain aminoacylated tRNA levels in malignant cells. We show that METTL1 copy number gain and elevated expression are a feature of pediatric tumors that are METTL1 dependent, using Cas13-mediated RNA to reduce the threshold of METTL1 mRNA and protein, which disrupts both catalytic and non-catalytic functions. In cell lines with METTL1 gene amplification, specific degradation of METTL1 mRNA impaired colony formation, triggered cell death, and decreased the translation efficiency of a subset of genes enriched for codons decoded m7G-modified tRNAs. METTL1 inhibition was accompanied by downregulation of c-MYC, n-MYC and MCL-1 protein expression. METTL1 silencing synergizes with drugs targeting anti-apoptotic members of the BCL2 family, notably BCL-xL. Importantly, the catalytic activity of METTL1 was required to rescue cells from the deleterious consequences of METTL1 silencing. We conclude that inhibiting the catalytic activity of METTL1 has potential therapeutic efficacy, particularly in tumors with METTL1 amplification. Synergistic combinations with BH3-mimetic drugs may be a promising therapeutic combination.